In these mice, liver-specific deletion of Stamp2 by in vivo siRNA delivery accelerated hepatic steatosis, as indicated by markedly increased vacuolization, increased liver weight, elevated plasma total cholesterol, triglyceride and nonesterified fatty acid levels, and increased insulin resistance. Here, STEAP4 is linked to Hepatic steatosis.